Skip to main content
. 2015 May 7;13:140. doi: 10.1186/s12967-015-0501-5

Figure 2.

Figure 2

Median progression-free survival (PFS) results. Kaplan-Meier curves for median PFS of colorectal cancer patients treated with irinotecan and cetuximab prospectively allocated in the unfavourable (-------) and favourable (———) arm (3 months vs. 8 months, p < 0.0001).